| abstract |
The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally--soluble bioactive agents such as, but not limited to, proteins of the TGF-.beta. superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. |